Convalescent plasma (CP) has emerged as a treatment for COVID-19. However, the
composition and mechanism of action are not fully known. Therefore, we undertook a two …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the
coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including …

Introduction The coronavirus disease 2019 (COVID-19) pandemic has spread globally.
Therapeutic options including antivirals, anti-inflammatory compounds, and vaccines are still …

Background The efficacy of coronavirus disease 2019 (COVID-19) convalescent plasma
(CCP) is primarily ascribed as a source of neutralizing anti-severe acute respiratory …

Introduction Passive antibody therapy has been used to immunize vulnerable people
against infectious agents. In this study, we aim to investigate the efficacy of convalescent …

Convalescent plasma (CP) transfusion has been indicated as a promising therapy in the
treatment for other emerging viral infections. However, the quality control of CP and …

Currently, there are no approved specific antiviral agents for novel coronavirus disease
2019 (COVID-19). In this study, 10 severe patients confirmed by real-time viral RNA test …

Objective To study the effectiveness of COVID-19 convalescent plasma (CCP) therapy for
patients with moderate and severe COVID-19 disease. Methods This non-randomized …

Clinical symptoms of COVID-19 include fever, cough, and fatigue which may progress to
acute respiratory distress syndrome (ARDS). The main hematological laboratory findings …

Abstract Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is a safe and
effective treatment for COVID-19 in immunocompromised (IC) patients. IC patients have a …